Physician profile
Simant Singh Thapa
NPI 1750765541
$430.21
in general payments reported to CMS, 2019-2025
11 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2022: $24.61 · 2023: $35.98 · 2024: $134 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.92 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $139.06 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $63.25 | 2019-2024 | Fasenra |
| Intuitive Surgical, INC. | $55.85 | 2024 | |
| Biogen, INC. | $41.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.54 | 2024 | Glassia |
| Regeneron Healthcare Solutions, INC. | $24.37 | 2025 | Dupixent |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.17 | 2019 | |
| Pfizer INC. | $15.30 | 2025 | |
| Viatris Specialty LLC | $15.13 | 2025 | Yupelri |
| Integra Lifesciences Corporation | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simant Thapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.